Adjuvant capecitabine for breast cancer after preoperative chemotherapy

New England Journal of Medicine

Volumn 376, Issue 22, 2017, Pages 2147-2159

  Masuda, N ^a   Lee, S J ^l   Ohtani, S ^b   Im, Y H ^m   Lee, E S ^t   Yokota, I ^c   Kuroi, K ^e   Im, S A ⁿ   Park, B W ^o   Kim, S B ^q   Yanagita, Y ^u   Ohno, S ^g   Takao, S ^h   Aogi, K ⁱ   Iwata, H ^j   Jeong, J ^p   Kim, A ^r   Park, K H ^s   Sasano, H ^k   Ohashi, Y ^f   Toi, M ^d   more..

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e Komagome Hospital   (Japan)

^f CHUO UNIVERSITY   (Japan)

^g GUNMA PREFECTURAL CANCER CENTER   (Japan)

^h NATIONAL KYUSHU CANCER CENTER   (Japan)

ⁱ HYOGO CANCER CENTER   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l TOHOKU UNIVERSITY   (Japan)

^m Young Nam University Hospital   (South Korea)

ⁿ Sungkyunkwan University School of Medicine   (South Korea)

^o Seoul National University Hospital   (South Korea)

^p Yonsei University College of Medicine   (South Korea)

^q Yonsei University College of Medicine   (South Korea)

^r Yonsei University College of Medicine   (South Korea)

^s Korea University College of Medicine   (South Korea)

^t College of Medicine   (South Korea)

^u National Cancer Center   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; LACTATE DEHYDROGENASE; TAXANE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FATIGUE; HAND FOOT SYNDROME; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SECOND CANCER; SOUTH KOREA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HAND-FOOT SYNDROME; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CAPECITABINE; CHEMOTHERAPY, ADJUVANT; FEMALE; HAND-FOOT SYNDROME; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85020023159     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1612645     Document Type: Article

References (37)

1. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and longterm clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-72.
2. Kuroi K, Toi M, Ohno S, et al. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer 2015; 22: 486-95.
3. National Comprehensive Cancer Network. Clinical practice guidelines in oncology (NCCN guidelines): breast cancer version 2. 2016 (https://www.nccn.org/professionals/physician-gls/pdf/breast.pdf).
4. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015; 26: 1533-46.
5. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-704.
6. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-21.
7. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an openlabel, randomised phase 3 trial. Lancet Oncol 2014; 15: 1389-96.
8. Martin M, Ruiz Simon A, Ruiz Borrego M, et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for nodepositive early breast cancer: results from the GEICAM/2003-10 study. J Clin Oncol 2015; 33: 3788-95.
9. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol 2012; 30: 11-8.
10. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93.
11. Miles D, von Minckwitz G, Seidman AD. Combination versus sequential singleagent therapy in metastatic breast cancer. Oncologist 2002; 7: Suppl 6: 13-9.
12. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
13. Pallis AG, Boukovinas I, Ardavanis A, et al. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol 2012; 23: 1164-9.
14. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24: 2019-27.
15. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual. 7th ed. New York: Springer, 2011.
16. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 2006; 13: 38-48.
17. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v3.0. August 9, 2006 (http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf).
18. Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan. Eur J Cancer 1996; 32A: 235-42.
19. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.
20. Taguchi T, Terasawa T, Abe O, Yoshida Y, Tominaga T, Ogawa N. A comparative study of 5'-DFUR and tegafur in recurrent breast cancer. Gan To Kagaku Ryoho 1985; 12: 2052-60. (In Japanese.)
21. Iwata H, Nakamura S, Toi M, et al. Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. Breast Cancer 2005; 12: 99-103.
22. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38: 163-70.
23. DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994; 13: 1341-52.
24. Toi M, Atiqur Rahman M, Bando H, Chow LW. Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 2005; 6: 158-66.
25. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
26. Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol 2015; 33: 2353-60.
27. Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 2010; 28: 2874-80.
28. Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colonystimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 2011; 29: 1014-21.
29. Leichman CG. Schedule dependency of 5-fluorouracil. Oncology (Williston Park) 1999; 13: Suppl 3: 26-32.
30. Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015; 16: 1037-48.
31. von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010; 28: 2015-23.
32. Ohno S, Chow LW, Sato N, et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat 2013; 142: 69-80.
33. O'Shaughnessy J, Koeppen H, Xiao Y, et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clin Cancer Res 2015; 21: 4305-11.
34. Lluch A, Gomez H, Ruiz-Borrego M, et al. First safety data from a randomised phase III (CIBOMA 2004- 01/GEICAM 2003-11) trial assessing adjuvant capecitabine maintenance therapy after standard chemotherapy for triple-negative early breast cancer. Presented at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010. abstract.
35. Mackean M, Planting A, Twelves C, et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16: 2977-85.
36. Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC. Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther 2012; 37: 266-75.
37. Haller DG, Cassidy J, Clarke SJ, et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008; 26: 2118-23.